Publication

Limited Sampling Strategies Using Linear Regression and the Bayesian Approach for Therapeutic Drug Monitoring of Moxifloxacin in Tuberculosis Patients

van den Elsen, S. H. J., Sturkenboom, M. G. G., Akkerman, O. W., Manika, K., Kioumis, I. P., van der Werf, T. S., Johnson, J. L., Peloquin, C., Touw, D. J. & Alffenaar, J-W. C., Jul-2019, In : Antimicrobial Agents and Chemotherapy. 63, 7, 13 p., ARTN e00384-19.

Research output: Contribution to journalArticleAcademicpeer-review

APA

van den Elsen, S. H. J., Sturkenboom, M. G. G., Akkerman, O. W., Manika, K., Kioumis, I. P., van der Werf, T. S., ... Alffenaar, J-W. C. (2019). Limited Sampling Strategies Using Linear Regression and the Bayesian Approach for Therapeutic Drug Monitoring of Moxifloxacin in Tuberculosis Patients. Antimicrobial Agents and Chemotherapy, 63(7), [ARTN e00384-19]. https://doi.org/10.1128/AAC.00384-19

Author

van den Elsen, Simone H J ; Sturkenboom, Marieke G G ; Akkerman, Onno W ; Manika, Katerina ; Kioumis, Ioannis P ; van der Werf, Tjip S ; Johnson, John L ; Peloquin, Charles ; Touw, Daan J ; Alffenaar, Jan-Willem C. / Limited Sampling Strategies Using Linear Regression and the Bayesian Approach for Therapeutic Drug Monitoring of Moxifloxacin in Tuberculosis Patients. In: Antimicrobial Agents and Chemotherapy. 2019 ; Vol. 63, No. 7.

Harvard

van den Elsen, SHJ, Sturkenboom, MGG, Akkerman, OW, Manika, K, Kioumis, IP, van der Werf, TS, Johnson, JL, Peloquin, C, Touw, DJ & Alffenaar, J-WC 2019, 'Limited Sampling Strategies Using Linear Regression and the Bayesian Approach for Therapeutic Drug Monitoring of Moxifloxacin in Tuberculosis Patients', Antimicrobial Agents and Chemotherapy, vol. 63, no. 7, ARTN e00384-19. https://doi.org/10.1128/AAC.00384-19

Standard

Limited Sampling Strategies Using Linear Regression and the Bayesian Approach for Therapeutic Drug Monitoring of Moxifloxacin in Tuberculosis Patients. / van den Elsen, Simone H J; Sturkenboom, Marieke G G; Akkerman, Onno W; Manika, Katerina; Kioumis, Ioannis P; van der Werf, Tjip S; Johnson, John L; Peloquin, Charles; Touw, Daan J; Alffenaar, Jan-Willem C.

In: Antimicrobial Agents and Chemotherapy, Vol. 63, No. 7, ARTN e00384-19, 07.2019.

Research output: Contribution to journalArticleAcademicpeer-review

Vancouver

van den Elsen SHJ, Sturkenboom MGG, Akkerman OW, Manika K, Kioumis IP, van der Werf TS et al. Limited Sampling Strategies Using Linear Regression and the Bayesian Approach for Therapeutic Drug Monitoring of Moxifloxacin in Tuberculosis Patients. Antimicrobial Agents and Chemotherapy. 2019 Jul;63(7). ARTN e00384-19. https://doi.org/10.1128/AAC.00384-19


BibTeX

@article{42df86576ad144deb9b44d2c4c8092a3,
title = "Limited Sampling Strategies Using Linear Regression and the Bayesian Approach for Therapeutic Drug Monitoring of Moxifloxacin in Tuberculosis Patients",
abstract = "Therapeutic drug monitoring (TDM) of moxifloxacin is recommended to improve the response to tuberculosis treatment and reduce acquired drug resistance. Limited sampling strategies (LSSs) are able to reduce the burden of TDM by using a small number of appropriately timed samples to estimate the parameter of interest, the area under the concentration-time curve. This study aimed to develop LSSs for moxifloxacin alone (MFX) and together with rifampin (MFX+RIF) in tuberculosis (TB) patients. Population pharmacokinetic (popPK) models were developed for MFX (n = 77) and MFX+RIF (n = 24). In addition, LSSs using Bayesian approach and multiple linear regression were developed. Jackknife analysis was used for internal validation of the popPK models and multiple linear regression LSSs. Clinically feasible LSSs (one to three samples, 6-h timespan postdose, and 1-h interval) were tested. Moxifloxacin exposure was slightly underestimated in the one-compartment models of MFX (mean -5.1{\%}, standard error [SE] 0.8{\%}) and MFX+RIF (mean -10{\%}, SE 2.5{\%}). The Bayesian LSSs for MFX and MFX+RIF (both 0 and 6 h) slightly underestimated drug exposure (MFX mean -4.8{\%}, SE 1.3{\%}; MFX+RIF mean -5.5{\%}, SE 3.1{\%}). The multiple linear regression LSS for MFX (0 and 4 h) and MFX+RIF (1 and 6 h), showed mean overestimations of 0.2{\%} (SE 1.3{\%}) and 0.9{\%} (SE 2.1{\%}), respectively. LSSs were successfully developed using the Bayesian approach (MFX and MFX+RIF; 0 and 6 h) and multiple linear regression (MFX, 0 and 4h; MFX+RIF, 1 and 6h). These LSSs can be implemented in clinical practice to facilitate TDM of moxifloxacin in TB patients.",
keywords = "drug interactions, population pharmacokinetics, sampling strategy, therapeutic drug monitoring, tuberculosis, MYCOBACTERIUM-TUBERCULOSIS, RESISTANT TUBERCULOSIS, POPULATION PHARMACOKINETICS, IN-VITRO, RIFAMPICIN, LEVOFLOXACIN, AMIKACIN, SAFETY, MODEL, QTC",
author = "{van den Elsen}, {Simone H J} and Sturkenboom, {Marieke G G} and Akkerman, {Onno W} and Katerina Manika and Kioumis, {Ioannis P} and {van der Werf}, {Tjip S} and Johnson, {John L} and Charles Peloquin and Touw, {Daan J} and Alffenaar, {Jan-Willem C}",
note = "Copyright {\circledC} 2019 American Society for Microbiology.",
year = "2019",
month = "7",
doi = "10.1128/AAC.00384-19",
language = "English",
volume = "63",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "1098-6596",
publisher = "AMER SOC MICROBIOLOGY",
number = "7",

}

RIS

TY - JOUR

T1 - Limited Sampling Strategies Using Linear Regression and the Bayesian Approach for Therapeutic Drug Monitoring of Moxifloxacin in Tuberculosis Patients

AU - van den Elsen, Simone H J

AU - Sturkenboom, Marieke G G

AU - Akkerman, Onno W

AU - Manika, Katerina

AU - Kioumis, Ioannis P

AU - van der Werf, Tjip S

AU - Johnson, John L

AU - Peloquin, Charles

AU - Touw, Daan J

AU - Alffenaar, Jan-Willem C

N1 - Copyright © 2019 American Society for Microbiology.

PY - 2019/7

Y1 - 2019/7

N2 - Therapeutic drug monitoring (TDM) of moxifloxacin is recommended to improve the response to tuberculosis treatment and reduce acquired drug resistance. Limited sampling strategies (LSSs) are able to reduce the burden of TDM by using a small number of appropriately timed samples to estimate the parameter of interest, the area under the concentration-time curve. This study aimed to develop LSSs for moxifloxacin alone (MFX) and together with rifampin (MFX+RIF) in tuberculosis (TB) patients. Population pharmacokinetic (popPK) models were developed for MFX (n = 77) and MFX+RIF (n = 24). In addition, LSSs using Bayesian approach and multiple linear regression were developed. Jackknife analysis was used for internal validation of the popPK models and multiple linear regression LSSs. Clinically feasible LSSs (one to three samples, 6-h timespan postdose, and 1-h interval) were tested. Moxifloxacin exposure was slightly underestimated in the one-compartment models of MFX (mean -5.1%, standard error [SE] 0.8%) and MFX+RIF (mean -10%, SE 2.5%). The Bayesian LSSs for MFX and MFX+RIF (both 0 and 6 h) slightly underestimated drug exposure (MFX mean -4.8%, SE 1.3%; MFX+RIF mean -5.5%, SE 3.1%). The multiple linear regression LSS for MFX (0 and 4 h) and MFX+RIF (1 and 6 h), showed mean overestimations of 0.2% (SE 1.3%) and 0.9% (SE 2.1%), respectively. LSSs were successfully developed using the Bayesian approach (MFX and MFX+RIF; 0 and 6 h) and multiple linear regression (MFX, 0 and 4h; MFX+RIF, 1 and 6h). These LSSs can be implemented in clinical practice to facilitate TDM of moxifloxacin in TB patients.

AB - Therapeutic drug monitoring (TDM) of moxifloxacin is recommended to improve the response to tuberculosis treatment and reduce acquired drug resistance. Limited sampling strategies (LSSs) are able to reduce the burden of TDM by using a small number of appropriately timed samples to estimate the parameter of interest, the area under the concentration-time curve. This study aimed to develop LSSs for moxifloxacin alone (MFX) and together with rifampin (MFX+RIF) in tuberculosis (TB) patients. Population pharmacokinetic (popPK) models were developed for MFX (n = 77) and MFX+RIF (n = 24). In addition, LSSs using Bayesian approach and multiple linear regression were developed. Jackknife analysis was used for internal validation of the popPK models and multiple linear regression LSSs. Clinically feasible LSSs (one to three samples, 6-h timespan postdose, and 1-h interval) were tested. Moxifloxacin exposure was slightly underestimated in the one-compartment models of MFX (mean -5.1%, standard error [SE] 0.8%) and MFX+RIF (mean -10%, SE 2.5%). The Bayesian LSSs for MFX and MFX+RIF (both 0 and 6 h) slightly underestimated drug exposure (MFX mean -4.8%, SE 1.3%; MFX+RIF mean -5.5%, SE 3.1%). The multiple linear regression LSS for MFX (0 and 4 h) and MFX+RIF (1 and 6 h), showed mean overestimations of 0.2% (SE 1.3%) and 0.9% (SE 2.1%), respectively. LSSs were successfully developed using the Bayesian approach (MFX and MFX+RIF; 0 and 6 h) and multiple linear regression (MFX, 0 and 4h; MFX+RIF, 1 and 6h). These LSSs can be implemented in clinical practice to facilitate TDM of moxifloxacin in TB patients.

KW - drug interactions

KW - population pharmacokinetics

KW - sampling strategy

KW - therapeutic drug monitoring

KW - tuberculosis

KW - MYCOBACTERIUM-TUBERCULOSIS

KW - RESISTANT TUBERCULOSIS

KW - POPULATION PHARMACOKINETICS

KW - IN-VITRO

KW - RIFAMPICIN

KW - LEVOFLOXACIN

KW - AMIKACIN

KW - SAFETY

KW - MODEL

KW - QTC

U2 - 10.1128/AAC.00384-19

DO - 10.1128/AAC.00384-19

M3 - Article

VL - 63

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 1098-6596

IS - 7

M1 - ARTN e00384-19

ER -

ID: 81818289